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Abstract 
Objective: To provide guidance on how systematic review authors, guideline developers, and 
health technology assessment practitioners should approach the use of the risk of bias in non-
randomized studies of interventions (ROBINS-I) tool as part of GRADE’s certainty rating process.    
Study Design and Setting: Iterative discussions, testing in systematic reviews, presentation at 
GRADE working group meetings with feedback from the GRADE Working Group. 
Results: We describe where to start the initial assessment of a body of evidence with the use of 
ROBINS-I, and where one would anticipate the final rating would end up. GRADE accounted for 
issues that mitigate concerns about confounding and selection bias by introducing the 
upgrading domains: large effects, dose-effect relations, and when plausible residual 
confounders or other biases increase certainty. They will need to be considered in an 
assessment of a body of evidence when using ROBINS-I.  
Conclusions: The use of ROBINS-I in GRADE assessments may allow for a better comparison of 
evidence from RCTs and NRS because they are placed on a common metric for risk of bias. 
Challenges remain that include appropriate presentation of evidence from RCTs and NRS for 
decision-making and how to optimally integrate RCTs and NRS in an evidence assessment.  
 
 
Key words 
GRADE, quality of evidence, certainty of the evidence, risk of bias, non-randomized studies, 
ROBINS 
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Highlights 
Key findings 
The risk of bias in non-randomized studies of interventions (ROBINS-I) tool addresses risk of bias in 
relation to a randomized trial presenting a number of opportunities for the GRADE approach. The 
GRADE Working Group addresses here how tools like ROBINS-I to assess risk of bias in observational or 
non-randomized studies should be used. The GRADE approach already accounted for issues that 
mitigate concerns about confounding and selection bias by introducing the upgrading domains: large 
effects, dose-effect relations, and when plausible residual confounders or other biases increase 
certainty. 
 
What this adds to what is known? 
In GRADE, the separation of randomized and observational studies was primarily a result of recognition 
that randomization is the only way to fully protect against confounding, and that confounding is always 
a concern in even the most rigorously conducted observational studies. Using the term non-randomized 
studies clarifies that all other designs but randomized trials are meant when evaluating observational 
studies in GRADE. 
 
What are the implications, what should change now? 
The use of ROBINS-I in GRADE assessments may allow for a better comparison of evidence from RCTs 
and non-randomized studies because they are placed on a common metric for risk of bias. The article 
describes the initial assessment of a body of evidence with the use of ROBINS-I, and where one would 
anticipate the final rating would end up.  
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1. GRADE’s approach to the certainty of the evidence from observational studies  
The GRADE working group has developed a widely accepted approach to rating the certainty of 
a body of evidence (also known as quality of evidence or confidence in evidence) in the 
contexts of systematic reviews, developing healthcare recommendations, and supporting 
decisions. GRADE’s approach to rating the certainty of the evidence is based on a four-level 
system: high, moderate, low and very low (Table 1). This is the 18
th
 in the ongoing series of 
articles describing the GRADE approach in the Journal of Clinical Epidemiology and 
complements articles in other journals. In previous GRADE articles we have described the 
reasons for decreasing and increasing the certainty of a body of evidence; how an overall rating 
of the evidence is performed; how evidence is utilized to move to recommendations and 
decisions; dealt with particular circumstances of diagnostic, prognostic, equity-related, multiple 
treatment comparison, environmental and public health questions; how GRADE applies to rapid 
advice; and when there is missing outcome data.(1-17)  
 
The current GRADE approach for a body of evidence relating to interventions begins by placing 
studies in one of two categories: randomized controlled trials (RCT) and observational studies 
(otherwise known as non-randomized studies, or NRS). GRADE considers non-randomized trials, 
cohort studies, case-control studies, interrupted-time series (if not randomized), cross sectional 
studies, case series, case reports and other types of non-randomized studies as observational 
studies.  
 
According to existing GRADE guidance for interventions, the process of rating a body of 
evidence (typically several or many studies) begins by classifying the design the relevant studies 
have used.  If the relevant studies are randomized trials, the body of evidence begins as high 
certainty.  If the relevant studies are observational, the body of evidence begins as low 
certainty.  This initial rating is followed by consideration of eight domains, five of which may 
result in rating down certainty, and three in rating up.(8)  
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The separation of randomized and observational studies was primarily a result of recognition 
that randomization is the only way to fully protect against confounding (i.e. imbalance in 
prognostic factors between intervention and control groups), and that confounding is always a 
concern in even the most rigorously conducted observational studies.  The imbalance in 
unknown prognostic factors that exists after statistical adjustment or stratified analysis to 
account for known variables which are not balanced in the exposed and the control groups is 
known as residual confounding.   
 
The choice of starting observational studies at low rather than moderate or very low certainty 
followed intense discussion in the GRADE working group’s early days, and was based on the 
group’s assessment of the magnitude of the potential for residual confounding, and the limited 
protection against bias provided by adjusted analysis in observational studies. An alternative 
way of understanding GRADE is that randomization is one of the reasons for rating certainty up 
as a measure to protect against confounding and selection bias.   
 
2. Rating risk of bias in individual observational studies 
Consider now the assessment of risk of bias in individual observational studies, which in the 
GRADE approach might lead to further rating down quality from low to very low.  Investigators 
have developed many assessment tools for rating risk of bias in observational studies. Most of 
the instruments address a specific type of observational or non-randomized design (e.g. cohort 
or case-control) (18), and seek to determine how well, relative to a perfect observational study 
of that particular design, the individual study at hand was conducted. An alternative approach 
is to determine risk of bias of observational studies in relation to the effect that would be seen 
in a high quality randomized trial. Such a trial avoids both confounding (through random 
allocation to interventions) as well as other sources of bias such as selection or information 
biases.  
 
The risk of bias in non-randomized studies of interventions (ROBINS-I) tool, rather than using 
the ideal observational study as a standard, addresses risk of bias using an absolute scale 
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approach.(19)  ROBINS-I evaluates risk of bias in estimates of the effects (harm or benefit) of 
one or more interventions from studies that did not use randomization to allocate units 
(individuals or clusters of individuals) to comparison groups (in GRADE terminology 
observational studies).  
 
ROBINS-I’s fundamental underlying principles are that (1) the study’s risk of bias is compared 
against a target RCT, even if this RCT may not be feasible or ethical; (2) the assessment of 
confounding and selection bias are integral parts of the tool; and (3) for a given result for a 
specific outcome, evidence from an NRS is assessed, addressing a number of domains and then 
giving an overall rating per outcome for each study. Figure 1 describes the application of 
ROBINS-I. Signaling questions in the ROBINS-I instrument ask respondents to rate RoB in 
domains of 1) Bias due to confounding, 2) Bias in selection of participants into the study, 3) Bias 
in classification of interventions, 4) Bias due to departures from intended interventions, 5) Bias 
due to missing data, 6) Bias in measurement of outcomes, and 7) Bias in selection of reported 
results (Figure 2). In addition, ROBINS-I includes an optional judgment about the direction of 
the bias for each domain. ROBINS-I has undergone careful development by a large group of 
experienced investigators. It has been tested and scientists have begun to validate it, and 
experience will continue to accumulate.  
 
3. ROBINS-I and GRADE 
The arrival of ROBINS-I presents a number of opportunities for the GRADE approach. First, it 
offers an alternative terminology: establishing NRS rather than observational studies. Although 
not different in intended meaning in the GRADE approach, substituting NRS for observational 
studies will lead to a more transparent separation of studies based on their design.  For 
instance, some have struggled with the classification of certain types of studies, such as non-
randomized before-after studies as observational; in the alternative nomenclature, such studies 
are clearly non-randomized.  How to classify studies that allocate by essentially random 
processes such as date of birth or hospital ID number, in which the concern is lack of 
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concealment rather than confounding bias per se, may remain a matter of debate that we will 
not address here. We will use the term NRS from here on in this article. 
 
Second, the use of ROBINS-I in GRADE assessments may allow for a better comparison of 
evidence from RCTs and NRS because they are placed on a common metric for risk of bias. This 
article provides guidance regarding how systematic review authors, guideline developers, and 
health technology assessment practitioners using GRADE might approach the use of ROBINS-I 
as part of the certainty rating process.  The article focuses on where to start the initial 
assessment of a body of evidence with the use of ROBINS-I, and where one would anticipate 
the final rating would end up. Implications and requirement for further work are dealt with in 
the final sections of this article.  This article will not resolve all relevant issues, and we plan 
subsequent articles describing the work of the GRADE RoB in NRS and environmental health 
project groups (www.gradeworkinggroup.org).  
 
4. Concerns about GRADE’s approach to start NRS at low certainty 
Despite GRADE’s broad acceptance in the evidence synthesis community, GRADE’s initial 
certainty rating of outcome data from NRS as low has led to challenges for some GRADE users.  
First, users of GRADE may inappropriately double count the risk of confounding and selection 
bias, initially by starting a body of evidence from NRS as low certainty of the evidence followed 
by again rating down for unknown confounders (although rating down additionally for failure to 
accurately measure known confounders and to adjust for these confounders in the analysis 
would be appropriate (Figure 3)). Second, those working in fields in which RCTs are sparse or 
not feasible have expressed concerns that NRS in their fields will seldom be rated as high or 
perhaps even moderate certainty. GRADE has accepted that criticism, highlighted how one may 
rate up certainty for large effects, a dose-response gradient, and if all plausible biases will 
strengthen rather than undermine inferences from study results. In this article, we note the 
merits of a rating system that follows the underlying logic of ROBINS-I and thus may better 
integrate RCTs and NRS and allow for more detailed assessment of different types of NRS. 
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While best evidence must be used for decision-making, relying on the best available or 
achievable rather than least biased evidence as a reference standard would lead to differing 
certainty in decisions based on the questions asked (20). Picture the following: in one scenario 
for a health care decision RCTs are neither ethical nor feasible and we, therefore, accept that 
possible confounded NRS are the reference standard for highest feasible certainty. If these 
studies are available we would express that we have high certainty in the decision despite the 
fact that confounding may bias the results. In the second scenario, RCTs are feasible and ethical 
and they become our reference standard for highest feasible certainty. If for this situation, only 
NRS are available, we would label our health care decision as based on low certainty. Should 
the certainty of the decision that is based on the respective evidence differ because of what 
evidence is available or should the certainty depend on what would be the highest possible 
certainty? It would be illogical to express different certainty for the same degree of bias 
because of feasibility and ethical reasons. A comparison on an absolute rather than relative (to 
the feasibility and ethics of an RCT) provides greater transparency. A decision can still be made 
for both scenarios and for both we should acknowledge the (same) degree of uncertainty. In 
fact, in most, if not all, areas of health care some interventions are supported by evidence from 
RCTs and others are not, requiring a common reference standard in order to ensure 
appropriate communication with target populations.  
 
Third, by beginning the rating of evidence from a body of NRS studies as low certainty, the 
current GRADE approach fails to consider that a body of evidence from particular NRS designs 
may more appropriately be rated higher than conventional NRS designs.  For instance, 
interrupted time series with multiple periods and measurements during each period and no 
other limitations may constitute moderate quality evidence without meeting any of the criteria 
for rating up (though our efforts to identify examples for such a body of evidence have not yet 
proved successful) (21). 
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5.  Certainty of evidence for a body of evidence from NRS when using ROBINS-I 
for assessing risk of bias in individual NRS 
Here, we provide general guidance for the use of GRADE in the context of ROBINS-I.  ROBINS-I 
compares an assessment of an individual NRS against a target RCT. The initial description of the 
underlying study design, such as cohort, case-control, case series or cross sectional study, is not 
considered as a risk of bias feature in ROBINS-I. Thus, when using ROBINS-I for assessing risk of 
bias in NRS, given that assessment of selection bias and confounding is an integral part of the 
ROBINS-I tool, the initial GRADE certainty in the evidence from a body of studies using an NRS 
design would be high (Figures 4 and 5).  This does not mean that GRADE has changed the view 
that randomization is the only secure way to guard against confounding bias; that view remains 
the same.  Thus, we would anticipate that whether one begins with a body of evidence from 
NRS studies as low certainty and looks for reasons to rate up or down, or starts with that 
evidence as high quality and looks for reasons to rate down, the final certainty rating should be 
the same.  
 
This approach implies that ROBINS-I users rating conventional NRS of any design (e.g. cohort, 
case-control) following their assessment of confounding and selection bias, will often arrive at a 
rating of high risk of bias.  Using ROBINS-I it nevertheless remains possible that a body of 
evidence from NRS studies will receive a final rating of high or moderate certainty of evidence.  
This could result from rating up for large effect, dose-response, or the direction of plausible 
confounding.  Or it could result from use of NRS designs and analyses with greater protection 
Box 1. Clarification of terminology 
GRADE uses the term “criteria” for all criteria in the evidence to decision frameworks of 
GRADE. Within these criteria the “certainty in the evidence” (or quality or strength of 
evidence) is one criterion. Certainty of the evidence is assessed based on “certainty 
domains” with individual items within each domain. RoB is one domain, therefore we will, in 
the context of GRADE, use the term RoB items to describe the 7 areas of judgment that 
ROBINS-I calls domains.  
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against risk of bias – for instance, interrupted time series – that would lead to rating down by 
only 1 level or not at all.  As we have already noted, however, while we have many examples of 
rating up certainty, efforts to identify a body of evidence from innovative designs meriting, 
simply for design considerations, moderate quality evidence, have thus far proved unsuccessful 
(Figure 4). Methodological developments in this area that describe how NRS may have greater 
protection against risk of bias than those typically available should help making such judgments 
but GRADE requires careful examination of these examples.(22)     
 
6. What makes us confident in results of NRS and does GRADE already account 
for this? 
At the end of the previous section we have noted how, within current GRADE thinking, a body 
of evidence from NRS studies may emerge from the rating exercise as moderate or high quality 
evidence.  We will now expand on these issues. 
6.1. All plausible residual confounders or other biases increase our certainty in the estimated 
effect 
GRADE allows higher certainty ratings for bodies of evidence when all plausible residual 
confounders or other biases increase our confidence in the range of an estimated effect, that is 
the effect is either larger or smaller than that observed (23, 24).  GRADE suggests that 
judgments about the direction of the possible bias are important to assess certainty of the 
evidence from NRS. One example from the public health field comes from a systematic review 
of NRS including a total of 38 million patients that demonstrated a very small relative increase 
(relative risk 1.020, 95% confidence interval 1.003-1.038) in death rates in private for-profit 
compared with private not-for-profit hospitals (23, 25). The evaluation of risk of bias across 
studies revealed that all residual plausible confounding – the major issues being that for-profit 
hospitals have on average higher income patients and greater resources - would have 
decreased the observed effect (further towards a RR of 1.0). Despite the biases in favour of for-
profit hospitals, those hospitals demonstrated higher mortality – therefore the true effect, if it 
differs from the estimate, is almost certain to be greater.   
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Currently, ROBINS-I allows for an optional judgment regarding the direction of confounding and 
selection bias (“Risk of bias judgment. Optional: What is the predicted direction of the of bias 
due to confounding/selection …”).  If this optional judgment is indeed used in ROBINS-I, in 
scenarios such as the hospital profit status example, not rating an individual NRS as high risk of 
bias (and thus not rating the body of evidence from a number of such studies as low certainty) 
is justified.  This may happen, albeit rarely, even in the context of small effects such as the one 
observed for the mortality risk in for-profit private hospitals.  
 
While GRADE has accounted for this situation in its approach, when users of GRADE apply 
ROBINS-I to assess risk of bias, the direction and degree of residual plausible confounding 
requires considering during the risk of bias assessment.  Rather than rating up NRS from low to 
moderate at the study and body of evidence level, raters using ROBINS-I may not rate risk of 
bias as very serious, but only rate it as moderate. Whether or not one starts at low certainty in 
the traditional GRADE approach and rates up or does not rate down to low when using ROBINS-
I, the end result is identical and depends on the risk of bias judgment (Figure 5).  
 
6.2. Large effects and dose responses 
GRADE suggests that large effects and dose-response relations mitigate concerns regarding 
residual confounding.  In one of our prior articles we described that a systematic review of NRS 
investigating the effect of cyclooxygenase-2 inhibitors on cardiovascular events found that the 
summary estimate of RR with rofecoxib of 1.33 (95% CI: 1.00 to 1.79) with doses less than 
25mg/d and 2.19 (95% CI: 1.64 to 2.91) with doses more than 25 mg/d. Can we infer that 
rofecoxib will increase the risk for cardiovascular events?  Although only NRS are available to 
address the question, we can have moderate, or perhaps even high, certainty of the causal 
connection.  The reasons are that, although residual confounding is likely to exist in the NRS 
that address this issue, the existence of a dose-response gradient and the large apparent effect 
of higher doses of rofecoxib markedly increase our strength of inference that the association 
cannot be explained by residual confounding, and is therefore likely to be both causal and, at 
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high levels of exposure, substantial.
1
  Given the large effect and the observed dose-response 
relation this could lead to a high certainty rating, for the outcome of increasing cardiovascular 
events.  
 
The previous paragraph dealt with evaluation of the entire body of evidence, which begs the 
question of how the rating of individual NRS of rofecoxib using ROBINS-I would impact on a 
GRADE assessment of the body of evidence .  The rater, in dealing with the confounding and 
selection bias domains would rate individual study as high risk of bias because of the possibility 
that residual confounding or selection bias may be influencing the estimates of association.  
How would one then deal with the dose-response and large effect size considerations when 
dealing with the body of evidence?   
 
In one way of looking at the situation, the subsequent rating up for large effects for the higher 
doses of rofecoxib would make, in retrospect, some of the items on the ROBINS-I tool 
potentially irrelevant.  The possible solutions are to a) rate the confounding in ROBINS-I as 
moderate or low risk of bias because large effects are observed and the larger the effect the 
stronger the confounding would have to be to explain the effect which makes an explanation by 
confounding unlikely; or b) leave the initial grading as low following the guidance above, and 
then rate up for large effects when one considers the entire body of evidence.  The same 
options exist with respect to dose-response relationships.  GRADE has thus accounted for issues 
that mitigate concerns about confounding and selection bias by introducing the upgrading 
domains. They will need to be considered in an assessment of a body of evidence when using 
ROBINS-I. 
  
7. Advantages and disadvantages of, in the context of GRADE, assessing risk of 
bias for individual studies using the ROBINS-I approach of specifying target trials  
7.1. Advantages  
                                                      
1
 GRADE guidance suggests the possibility of rating up one level for a large effect if the relative effect is greater 
than 2.0.  Here, the fact that the point estimate of the relative effect is greater than 2.0, but the confidence 
interval is appreciably below 2.0 might make some hesitate in the decision to rate up for a large effect. 
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Among other features, ROBINS-I allows review authors to assess how failure to use 
randomization in individual studies has impacted on risk of bias. For example, ROBINS-I allows a 
categorization of the magnitude of bias from lack of randomization through the selection and 
confounding bias domains, allows application of this assessment across risk of bias domains, 
and evaluation of how this differs across individual studies that address different health care 
questions. Furthermore, ROBINS-I will facilitate assessment of a study that has been described 
as randomized but when assessed in detail is found to be not appropriately randomized. In 
those cases, users of GRADE have struggled with whether to start the certainty of evidence as 
high and then rate it down, or ignore descriptions of the study authors and treat the studies as 
NRS by starting the certainty of evidence as low.  All these features of the assessment of 
individual studies can then be taken into account when evaluating a group of individual studies 
that constitute a body of evidence. 
 
Another potential advantage of using an approach such as ROBINS-I is that it may harmonize 
GRADE approaches across different study types for different types of questions such as 
prognosis or test accuracy. In the current GRADE approach, NRS studies for these types of 
questions begin with high certainty ratings.  In particular, with prognostic studies, in which the 
issue is association and not causation, prognostic NRS begin as high certainty evidence. If 
GRADE assessments for  all types of studies were to start at high certainty, questions of 
intervention, prognosis, values and preferences, and test accuracy, would not require different 
initial certainty ratings.  What will be required, however, are different versions of ROBINS, such 
as ROBINS tool for prognosis.   
 
Finally, those applying GRADE in fields where RCTs are sparse such as environmental and 
certain areas of public health, reframing the certainty assessment with a focus on the actual 
items that randomization addresses, i.e. confounding and selection bias, rather than labeling a 
study design feature, i.e. randomization, will find GRADE more acceptable.  
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6.2. Disadvantages 
The disadvantages of offering an alternative to the existing GRADE system include mistakes if 
users of GRADE do not follow the approach appropriately. First, ROBINS-I is currently the only 
available tool that explicitly includes a comparison against RCTs (and this situation is unlikely to 
change) and thus this guidance only applies to the situations when ROBINS-I is used. Second, 
because of the advantage of assessing risk of bias on an absolute scale, use of ROBINS-I may 
facilitate combining results of RCTs and NRS. However, under what conditions one should 
combine results from randomized and non-randomized studies remains uncertain (this 
uncertainty also applies whether one uses ROBINS-I or other instruments for assessing risk of 
bias in NRS) (Figure 4).  
Third, there is a possibility of misuse by those wanting to assign a higher certainty of the 
evidence to a body of evidence from NRS than is appropriate. Evaluators of evidence may rate 
the risk of bias from a group of NRS as moderate risk of bias if they are not appropriately 
cautious about the impact of confounding and selection bias or if reporting is poor.  Users of 
GRADE may then take the results of such studies and classify them as moderate certainty (if no 
problems in other GRADE domains exist) when, following current GRADE guidance, they should 
be classified as low certainty.  This may result from a higher threshold and requirement for 
documenting upgrading rather than a potentially higher threshold for rating down NRS when 
using ROBINS-I. Fourth, further, detailed guidance is required for appropriate application of 
ROBINS-I with more examples as concerns about the amount of time required and the lack of 
detailed reporting of risk of bias related items in current NRS. Fifth, until now there is no 
practical example on which to base a rating of initial high or even moderate certainty in the 
evidence that comes from a body of evidence from NRS where no traditional GRADE upgrading 
domain applies.   
 
8. Unresolved Issues 
GRADE recognizes that there are a number of unresolved issues related to the arrival of 
ROBINS-I. The GRADE working group is addressing those in the near future. The unresolved 
issues are as follows: 
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1. If systematic review authors use ROBINS-I, should the results from NRSs and RCTs be 
considered together, including potentially in a meta-analysis (Figure 4).  If RCTs and NRS are 
indeed considered together, when should they be combined? Should non-randomized studies 
be utilized to provide more precise estimates in summary effects when in fact NRS may 
dominate such estimates? Should they be used to alleviate concerns about indirectness 
because they are often including broader populations and more practice oriented 
interventions? Should we continue to follow GRADE guidance to generally separate randomized 
and non-randomized study results in GRADE summary tables such as evidence profiles and 
Summary of Findings tables or should the guidance be modified? Until clear advice on when to 
combine data form randomized and non-randomized studies is available, we suggest following 
current GRADE guidance: if certainty of evidence differs in a body of randomized trials and a 
body of NRS, one need only present in summary of findings (SoF) tables, the higher certainty 
evidence (almost invariably that from RCTs).  If certainty ratings are the same (typically low 
certainty) one presents results from the two bodies of evidence separately.  If the results are 
consistent, then the overall certainty assessment is that of the two bodies of evidence (typically 
low certainty).  If the results are inconsistent, and one believes both bodies of evidence should 
be taken into consideration, then one will rate down further for this inconsistency, and the final 
rating will be one category lower (typically very low certainty).  
2. How should we deal with publication bias in the context of including NRS, clearly posing more 
challenges than evaluating publication bias in RCTs (available evidence suggests publication bias 
is a greater problem in NRS than in RCTs)?   
3. Under what circumstances should evidence syntheses broaden their scope of search and 
consider NRS routinely? 
4. GRADE needs to develop more detailed guidance than currently exists regarding the 
presence of large effects and dose-effect relations. With regards to large effects, if a body of 
evidence from NRS is indeed rated as high-certainty in the evidence prior to the consideration 
of size of effect and very large effects exist, no further rating up is possible or required. This is 
also the situation regarding how GRADE currently deals with large effects observed in a body of 
evidence from RCTs. For instance, the large relative risk reduction observed with oral 
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anticoagulation for the treatment of DVT for prevention of stroke in patients with atrial 
fibrillation does not lead to an ultimate rating of the certainty of the evidence beyond high. 
5. Currently GRADE has only three labels for risk of bias: not serious, serious or very serious on 
the risk of bias domain levels. For RCTs, this corresponds to a rating of the body of evidence as 
high, moderate or low certainty of evidence after considering risk of bias; for NRS this means 
that when GRADE currently uses serious risk of bias for NRS they are rated down from low 
initial certainty to very low. When raters use ROBINS-I with NRS beginning at high certainty, 
three levels for rating down for risk of bias are required so that NRS can arrive at a rating of 
very low certainty after considering risk of bias. GRADE is now exploring the best labelling 
options which include the use of not serious, serious, very serious and very, very serious leading 
to certainty ratings of high, moderate, low and very low after risk of bias assessment. 
9. Summary and next steps 
Risk of bias can be best mitigated by a well conducted RCT that balances known and unknown 
confounders, and using the Cochrane RoB 2.0 tool or similar assessment tools for RCTs to assess 
risk of bias.  For situations in which NRS are used instead or in addition to RCTs, the arrival of 
ROBINS-I poses a number of opportunities and challenges to summarizing RoB in GRADE, and 
raises a need for clarification about how ROBINS-I and GRADE are used together.  Given the 
inherent limitations of studies that do not use randomization, a body of evidence from NRS 
studies should generally not lead to moderate or high certainty in the evidence in relation to 
risk of bias. Raters using GRADE should always consider confounding and selection bias as 
reasons for rating down a body of evidence, and this is achieved in the current GRADE by 
assigning an initial rating of low certainty.  
For studies of interventions that are assessed with ROBINS-I in the context of GRADE, we 
suggest that an initial rating of high is used, with appropriate consideration of the impact of 
lack of randomization leading to rating down for risk of bias according to the ROBINS-I tool. In 
practice this will generally lead to rating down by at least two levels to low or very low certainty 
for NRS. However, for results with large effects, or dose response, or results in which inference 
is strengthened by the plausible biases that exist, the extent of rating down may be lowered. 
We have not identified bodies of evidence in which a ROBINS-I assessment alone leads to no 
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rating down, or rating down by only one level. We therefore invite users of ROBINS-I and those 
who produce summary of findings tables or evidence profiles to submit to the GRADE working 
group any examples of when they believe that NRS studies without reasons for rating up 
warrant moderate or high certainty evidence.  
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Table 1. Use of GRADE not considering ROBINS-I and similar tools: According to GRADE, certainty, quality, strength of the evidence 
or the confidence in the estimate of effect, is determined for each outcome based on a systematic review of the evidence for each 
outcome.  For recommendations, the overall certainty is determined across outcomes based on the lowest quality outcome among 
those critical for decision-making for the specific context.   
 
1.  
Establish initial 
level of certainty (as implemented in 
current GRADE) 
 2.  
Consider lowering or raising 
level of certainty 
 3.  
Final level of  
certainty rating  
Study design Initial certainty 
in the evidence 
 Reasons for considering lowering  
or raising certainty  
 Certainty in the evidence  
across those considerations 
   Lower if    Higher if* 
Randomized trials 
High 
certainty 
Risk of Bias 
Inconsistency 
Indirectness 
Imprecision 
Publication bias 
Large effect 
Dose response 
All plausible  
confounding and 
bias 
• would reduce a 
demonstrated effect  
   or 
• would suggest a 
spurious effect if no 
effect was observed 
High 
⊕⊕⊕⊕ 
  
Moderate 
⊕⊕⊕ 
Observational studies 
Low 
certainty 
Low 
⊕⊕ 
  
Very low 
⊕ 
 
*Criteria for upgrading the quality are usually only applicable to observational studies without any reason for rating down. 
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Figure 1. The process for using ROBINS-I 
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Figure 2. ROBINS-I risk of bias domains  
 
 
 
Figure caption: In GRADE risk of bias is a domain and ROBINS-I domains are called items) 
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Figure 3. The current GRADE approach for certainty of evidence: initial certainty and rating domains 
 
 
  
• RCTs ⊕⊕⊕⊕ | high 
• observa onal studies ⊕⊕   | low 
• 5 domains that can lower certainty 
1. limita ons in detailed study design and execu on 
(risk of bias items) 
2. Inconsistency (or heterogeneity) 
3. Indirectness (PICO and applicability) 
4. Imprecision 
5. Publica on bias  
• 3 domains can increase certainty 
1. large magnitude of effect 
2. opposing plausible residual bias or confounding 
3. dose-response gradient 
Risk of bias 
Determinants of certainty of evidence 
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Figure 4. Assessing randomized trials and non-randomized studies with GRADE 
 
Figure caption: Rating of risk of bias for randomized and non-randomized studies. Different tools are used to address for the two 
types of bodies of evidence (randomized and non-randomized). The risk of bias is then assessed across studies and integrated if 
possible. When ROBINS-I is used rating down by more than two levels is required for a body of evidence that is rated as critical on 
that instrument.  
*In practice this will generally lead to rating down by at least two levels to low or very low certainty for NRS. However, for results 
with large effects, or dose response, or results in which inference is strengthened by the plausible biases that exist, the extent of 
rating down may be lowered. We have not identified bodies of evidence in which a ROBINS-I assessment alone leads to no rating 
down, or rating down by only one level. How to integrate RCTs and NRS will be further discussed in upcoming GRADE guidance 
articles. 
RCTs
ROBINS-I
Start high*
NRS
RCT RoB Tool 
Start High
Risk of bias
on study level
GRADE RoB
(each body of 
evidence)
Low risk of bias (no 
downgrading)
Moderate risk of bias 
(downgrade by one level)
Serious risk of bias 
(downgrade by two levels)
Critical risk of bias**
(downgrade by three levels)
No serious risk of bias
Serious risk of bias 
(downgrade)
Very serious risk of bias
(downgrade by two levels)
Risk of bias
across RCTs 
and NRS
GRADE RoB
(body of 
evidence)
Risk of bias
across 
studies
No serious risk of 
bias
Serious risk of bias 
(downgrade by one 
level)
Very serious risk of 
bias (downgrade by 
two level)
**More than very 
serious (downgrade 
by three levels)
❓
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** For GRADE the corresponding terminology is not serious, serious, very serious and a fourth level of risk of bias. GRADE is currently 
exploring the appropriate term for the fourth level  
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Figure 5. GRADE approach for certainty of evidence with tools like ROBINS-I 
 
 
 
 
• RCTs and NRS ⊕⊕⊕⊕ | high 
• Domains that can lower certainty 
1. limita ons in detailed study design and execu on 
(risk of bias items) 
• Lack of randomiza on lowers certainty to low unless opposing 
plausible residual bias strengthens certainty or special study 
designs that reduce confounding and selec on bias  
2. Inconsistency (or heterogeneity) 
3. Indirectness (PICO and applicability) 
4. Imprecision 
5. Publica on bias  
• Domains can increase certainty or mi gate risk of 
bias 
1. large magnitude of effect 
2. dose-response gradient 
Certainty of evidence with tools like ROBINS-I 
